News
Filter By:
- All
- Blog
- In the News
- Press Releases
- Publications
- All
- Blog
- In the News
- Press Releases
- Publications
Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Meeting and SynBioBeta Global Synthetic Biology Conference
WATERTOWN, Mass., April 23, 2024 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential ...
Read More →
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies
– 80x improvement vs. AAV2 in delivery to the retina seen in non-human primate (NHP) – – Head-to-head against other retina-IVT capsids, Dyno eCap 1 ...
Read More →
Dyno Therapeutics to Present on Breakthrough Optimized AAV Capsids for Eye and CNS Gene Delivery at ESGCT Annual Congress
WATERTOWN, Mass., October 11, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that expand the potential ...
Read More →
Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence
– Dyno bCap 1 exhibits 100x improvement versus AAV9 in delivery to the central nervous system (CNS) and 10x detargeting of liver after intravenous (IV) ...
Read More →
Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
WATERTOWN, Mass., May 2, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the ...
Read More →
Dyno is scaling gene therapy research with cloud-native tools like Argo Workflows and Hera
Cloud native tools such as Kubernetes and Argo Workflows are improving productivity, accelerating innovation, and increasing operational efficiency. These tools reduce the burden of infrastructure ...
Read More →
Leadership Updates
BOSTON, MA — April 25, 2023— We are pleased to announce the promotion of Adam Poulin-Kerstien, JD, PhD to General Counsel & appointment of Adrian Veres, ...
Read More →
Dyno Therapeutics Named on the Forbes List of America’s Best Startup Employers 2022
BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. ...
Read More →
Hera – the missing Argo Workflows Python SDK
At Dyno, we believe in collective innovation on our journey of empowering a diverse team of the best problem solvers to drive cutting edge science ...
Read More →
Dyno Therapeutics at Goldman Sachs Byte-ology Conference
Discussing the Convergence of Biotechnology and Technology Boston, Dec. 9, 2021 – Dyno Therapeutics announced today that management is scheduled to participate at the Goldman ...
Read More →
Dyno Therapeutics Named Emerging Company of the Year at New England Venture Capital Association’s 2021 NEVY Awards
BOSTON, MA — December 6, 2021— Dyno Therapeutics has announced it was selected for the Emerging Company of the Year Award in the Life ...
Read More →
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion TOKYO and CAMBRIDGE, Mass., Dec. 2, 2021 – Astellas Pharma Inc. (TSE: ...
Read More →
Our Focus on Mission Driven Collective Innovation
Dyno empowers a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. Our mission is to build the ideal capsid ...
Read More →
The Endpoints 11: They’ve got mad money and huge ambitions. It’s time to go big or go home
These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A ...
Read More →
Introduction to AAV as a Gene Therapy Vector, Part 2
What are AAVs? and what makes them good candidates for gene therapy? By: Christopher Reardon, Stephen Malina, and Eryney Marrogi Introduction In the first part ...
Read More →
